Antipsychotic switching in bipolar disorders: A systematic review

International Journal of Neuropsychopharmacology

Volumn 17, Issue 3, 2014, Pages 497-507

  Grande, Iria ^a   Bernardo, Miquel ^b   Bobes, Julio ^c   Saiz Ruiz, Jerónimo ^d   Álamo, Cecilio ^e,f   Vieta, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e UNIVERSITY OF GRANADA   (Spain)

^f UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antipsychotics; Bipolar disorder; Mood stabilizer; Switching; Tolerance

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG SUBSTITUTION; HUMANS;

EID: 84897906114     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001168     Document Type: Review

References (61)

1. Bernardo M, Vieta E, Sáiz-Ruiz J, Rico-Villademoros F, Alamo C, Bobes J (2011) Recomendations for switching antispychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment 4:150-168.
2. Bobo WV, Stovall JA, Knostman M, Koestner J, Shelton RC (2010) Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data. Am J Health Syst Pharm 67:27-37.
3. Bogan AM, Shellhorn E, Brown ES, McDanald C, Suppes T (2000) Switching outpatients between atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 24:351-355.
4. Brown ES, Jeffress J, Liggin JDM, Garza M, Beard L (2005) Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66:756-760.
5. Buckley PF (2007) Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 68(Suppl. 6):5-9.
6. Buckley PF, Correll CU (2008) Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 69(Suppl. 1):4-17.
7. Chandrasena R, Dvoráková D, Lee SI, Loza N, Mosolov SN, Osváth P, Pregelj P, Walton RJ, Karagianis J, Treuer T (2009) Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Int J Clin Pract 63:1249-1258.
8. Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY (2012) Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol 26:1201-1210.
9. Cipriani A, Rendell J, Geddes JR (2010) Olanzapine in the longterm treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24:1729-1738.
10. Colom F, Vieta E (2011) The need for publishing the silent evidence from negative trials. Acta Psychiatr Scand 123:91-94.
11. Correll CU (2011) What are we looking for in new antipsychotics? J Clin Psychiatry 72(Suppl. 1):9-13.
12. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (2010) Efficacy of modern antipsychotics in placebocontrolled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 13:5-14.
13. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S (2012) Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 26:603-617.
14. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126.
15. Di Sciascio G, Calo S, Amodio G, D'Onofrio S, Pollice R (2011) The use of first generation vs. second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting. Int J Immunopathol Pharmacol 24:225-230.
16. El-Mallakh RS, Ketter TA, Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Keck P, Swann AC, Kalali AH (2008) Switching from other agents to extended-release carbamazepine in acute mania. Psychopharmacol Bull 41:52-58.
17. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, Versiani M, Tandon R, Möller H-J, Vieta E (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262(Suppl.):1-48.
18. Frye MA, Ha K, Kanba S, Kato T, Özerdem A, Vázquez G, Vieta E (2011) International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 72:1295-1310.
19. Gardner DM, Baldessarini RJ, Benzo J, Zarate CAJ, Tohen M (1997) Switching between clozapine and risperidone treatment. Can J Psychiatry 42:430-431.
20. Goikolea JM, Colom F, Capapey J, Torres I, Valenti M, Grande I, Undurraga J, Vieta E (2013) Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol 23:302-316.
21. Goodwin GM, Abbar M, Schlaepfer TE, Grunze H, Licht RW, Bellivier F, Fountoulakis KN, Altamura AC, Pitchot W, Agren H, Holsboer-Trachsler E, Vieta E (2011) Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Curr Med Res Opin 27:2285-2299.
22. Grande I, Pons A, Baeza I, Torras A, Bernardo M (2011) QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum Psychopharmacol 26:397-403.
23. Grande I, Balanzá-Martínez V, Jiménez-Arriero M, Iglesias Lorenzo FG, Franch Valverde JI, de Arce R, Zaragoza S, Cobaleda S, Vieta E (2012) Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study. J Affect Disord 143:102-108.
24. Grande I, de Arce R, Jiménez-Arriero MÁ, Lorenzo FGI, Valverde JIF, Balanzá-Martínez V, Zaragoza S, Cobaleda S, Vieta E (2013) Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol 16:513-523.
25. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, Kasper S (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14:154-219.
26. Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch J, Vieta E (2011) 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery. Eur Neuropsychopharmacol 21:287-293.
27. Hilwerling L, Juckel G, Schröder SG (2007) Quetiapine indication shift in the elderly: diagnosis and dosage in 208 psychogeriatric patients from 2000 to 2006. Int J Geriatr Psychiatry 22:401-404.
28. Kemp DE, Karayal ON, Calabrese JR, Sachs GS, Pappadopulos E, Ice KS, Siu CO, Vieta E (2012) Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol 22:123-131.
29. Kluznik JC, Walbek NH, Farnsworth MG, Melstrom K (2001) Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry 62(Suppl. 5):14-17.
30. Koener B, Hermans E, Emmanuel H, Maloteaux J-M, Jean-Jean A, Constant EL (2007) Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole. Am J Psychiatry 164:1437-1438.
31. Liauw SS, McIntyre RS (2010) Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother 11:2827-2837.
32. Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35:1520-1530.
33. Medori R, Braunig P, Sacchetti E (2005) Bipolar disorder: 6-months efficacy of risperidone injectable. World J Biol Psychiatry 6(Suppl. I):192-193.
34. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.
35. Murru A, Colom F, Nivoli A, Pacchiarotti I, Valenti M, Vieta E (2011a) When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological onsiderations. Eur Psychiatry 26:183-186.
36. Murru A, Pacchiarotti I, Nivoli AMA, Grande I, Colom F, Vieta E (2011b) What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol 21:680-690.
37. Nivoli AMA, Colom F, Murru A, Pacchiarotti I, Castro-Loli P, González-Pinto A, Fountoulakis KN, Vieta E (2011a) New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 129:14-26.
38. Nivoli AMA, Murru A, Goikolea JM, Crespo JM, Montes JM, González-Pinto A, García-Portilla P, Bobes J, Sáiz-Ruiz J, Vieta E (2011b) New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 140:125-141.
39. Nivoli AMA, Colom F, Pacchiarotti I, Murru A, Scott J, Valentí M, Mazzarini L, Del Mar Bonnin C, Sánchez-Moreno J, Serretti A, Vieta E (2013) Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options. Eur Neuropsychopharmacol 23:263-275.
40. Pae C-U, Lee K-U, Kim J-J, Lee C-U, Bahk W-M, Lee S-J, Lee C, Paik I-H (2004) Switching to quetiapine in patients with acute mania who were intolerant to risperidone. Hum Psychopharmacol 19:47-51.
41. Popovic D, Reinares M, Amann B, Salamero M, Vieta E (2011) Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 213:657-667.
42. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E (2012) Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 22:339-346.
43. Rachid F, Bertschy G, Bondolfi G, Aubry J-M (2004) Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 65:1537-1545.
44. Reinares M, Rosa AR, Franco C, Goikolea JM, Fountoulakis K, Siamouli M, Gonda X, Frangou S, Vieta E (2012) A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 16:485-496.
45. Savas HA, Yumru M, Ozen ME (2006) Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 26:530-531.
46. Spurling RD, Lamberti JS, Olsen D, Tu X, TangW(2007) Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 68:406-409.
47. Stahl SM (2013) Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment 6:97-100.
48. Torrent C, Martinez-Arán A, Daban C, Amann B, Balanzá- Martínez V, del Mar Bonnín C, Cruz N, Franco C, Tabarés-Seisdedos R, Vieta E (2011) Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 52:613-622.
49. Urrútia G, Bonfill X (2010) PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses. Med Clín (Barc) 135:507-511.
50. Vieta E, Cruz N (2012) Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol 22:800-803.
51. Vieta E, Valentí M (2013a) Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 148:28-36.
52. Vieta E, Valentí M (2013b) Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 27:515-529.
53. Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Aström M, Paulsson B, Gu O, Mikael A (2011) Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 14:1029-1049.
54. Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, Schreiner A (2012) A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 22:825-835.
55. Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, Moreno-Manzanaro M, Gonzalez MA, Bellivier F (2013) Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol 13:1-14.
56. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2011) Continuation of quetiapine vs. switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72:1452-1464.
57. Wilting I, Souverein PC, Nolen WA, Egberts ACG, Heerdink ER (2008) Changes in outpatient lithium treatment in the Netherlands during 1996-2005. J Affect Disord 111:94-99.
58. Yang F-W, Liang C-S (2011) Manic symptoms during a switch from risperidone to paliperidone: a case report. J Neuropsychiatry Clin Neurosci 23:E29.
59. Yatham LN, Fallu A, Binder CE (2007) A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Supplementum 116:50-56.
60. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11:225-255.
61. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36:375-389.